US · RVMDW · BIOTECHNOLOGY
Revolution Medicines, Inc. Warrant (RVMDW) intrinsic value and stock valuation
$6.40as of 2026-11-21 · Mkt cap 41.8B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Revolution Medicines, Inc. Warrant DCF and intrinsic value
InvestorsCraft values RVMDW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RVMDW’s statements →
Revolution Medicines, Inc. Warrant Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- ImmuCell Corporation (ICCC) $10.92
- Fortress Biotech, Inc. (FBIO) $1.90
- vTv Therapeutics Inc. (VTVT) $15.51
- Acrivon Therapeutics, Inc. Common Stock (ACRV) $1.15
- Telomir Pharmaceuticals, Inc. Common Stock (TELO) $0.36
- Estrella Immunopharma, Inc. (ESLA) $0.32
- BioXcel Therapeutics, Inc. (BTAI) $0.07
- Tempest Therapeutics, Inc. (TPST) $0.29
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $11.6M | $35.4M | $29.4M |
| Operating income | -$-1.18B | -$-689.52M | -$-487.19M | -$-258.28M | -$-188.01M |
| Net income | -$-1.13B | -$-600.09M | -$-436.37M | -$-248.71M | -$-187.09M |
| EPSd | -$-5.95M | -$-3.58M | -$-3.86M | -$-3.08M | -$-2.57M |
| Operating cash flow | -$-897.74M | -$-557.44M | -$-350.57M | -$-224.4M | -$-147.18M |
| Capital expenditure | -$-15.99M | -$-10.31M | -$-7.73M | -$-10.82M | -$-6.53M |
| Free cash flow | -$-913.73M | -$-567.74M | -$-358.3M | -$-235.22M | -$-153.71M |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738M |
| Total debt | $158.7M | $135.8M | $87.9M | $64.2M | $66.6M |
| Net debt | -$-225.04M | -$-407.22M | -$-608.2M | -$-97.21M | -$-41.86M |
| Total equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M |
| Cash and short-term investments | $2.03B | $2.29B | $1.85B | $644.9M | $577.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $11.6M | $35.4M | $29.4M |
| Cost of revenue | $16.6M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | -$-16.56M | $0.00 | $11.6M | $35.4M | $29.4M |
| Research and development expenses | $978.7M | $592.2M | $423.1M | $253.1M | $187M |
| Selling, general and administrative expenses | $187.1M | $97.3M | $75.6M | $40.6M | $30.5M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $1.17B | $689.5M | $498.8M | $293.7M | $217.4M |
| Cost and expenses | $1.18B | $689.5M | $498.8M | $293.7M | $217.4M |
| Interest income | $90.7M | $86.9M | $47.5M | $9.15M | $930K |
| Interest expense | $24.2M | $0.00 | $300K | $0.00 | $10K |
| Depreciation and amortization | $16.6M | $11.8M | $9.31M | $9.66M | $7.33M |
| Ebitda | -$-1.09B | -$-589.02M | -$-430.28M | -$-239.47M | -$-179.75M |
| Operating income | -$-1.18B | -$-689.52M | -$-487.19M | -$-258.28M | -$-188.01M |
| Total other income/expenses, net | $51.1M | $88.7M | $47.3M | $9.15M | $920K |
| Income before tax | -$-1.13B | -$-600.85M | -$-439.89M | -$-249.12M | -$-187.09M |
| Income tax expense | $0.00 | -$-750K | -$-3.52M | -$-420K | $0.00 |
| Net income | -$-1.13B | -$-600.09M | -$-436.37M | -$-248.71M | -$-187.09M |
| Weighted average shares outstanding | $190.1M | $167.7M | $113.2M | $80.6M | $72.8M |
| Weighted average diluted shares outstanding | $190.1M | $167.7M | $113.2M | $80.6M | $72.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $2.03B | $2.29B | $1.85B | $644.9M | $577.1M |
| Net receivables | $0.00 | $0.00 | $1.25M | $4.67M | $5.93M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $2.08B | $2.33B | $1.88B | $660.2M | $589.8M |
| Property, plant and equipment, net | $165.3M | $141.8M | $100M | $73.7M | $71.2M |
| Goodwill and intangible assets | $70.4M | $71.3M | $72.4M | $73.4M | $74.5M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $279.5M | $230.7M | $182.4M | $151.8M | $148.2M |
| Total assets | $2.35B | $2.56B | $2.06B | $811.9M | $738M |
| Accounts payable | $64.6M | $54.4M | $61.8M | $21.3M | $14.1M |
| Short-term debt | $16.5M | $12.9M | $7.37M | $6.77M | $6.21M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $4.46M | $12.4M |
| Total current liabilities | $290.4M | $163.9M | $143.9M | $62M | $60.4M |
| Long-term debt | $142.2M | $123M | $80.6M | $57.4M | $60.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $6.57M |
| Total non-current liabilities | $432.8M | $129.2M | $91.7M | $64.8M | $75.1M |
| Capital lease obligations | $16.5M | $135.8M | $87.9M | $64.2M | $66.6M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M |
| Common stock | $20K | $20K | $20K | $10K | $10K |
| Retained earnings | -$-2.87B | -$-1.74B | -$-1.14B | -$-701.34M | -$-452.64M |
| Accumulated other comprehensive income (loss) | $3.24M | $1.32M | $540K | -$-1.78M | -$-380K |
| Total equity | $1.63B | $2.27B | $1.83B | $685.2M | $602.6M |
| Total investments | $1.64B | $1.75B | $1.16B | $483.5M | $468.6M |
| Total debt | $158.7M | $135.8M | $87.9M | $64.2M | $66.6M |
| Net debt | -$-225.04M | -$-407.22M | -$-608.2M | -$-97.21M | -$-41.86M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-1.13B | -$-600.09M | -$-436.37M | -$-248.71M | -$-187.09M |
| Depreciation and amortization | -$-26.96M | $11.8M | $9.31M | $9.66M | $7.33M |
| Stock-based compensation | $118.4M | $79.2M | $61.8M | $31.2M | $20.7M |
| Change in working capital | $86.8M | $1.17M | $40.7M | -$-13.49M | $8.72M |
| Accounts receivable | $0.00 | $1.25M | $3.42M | $1.26M | $460K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $7.68M |
| Accounts payable | $9.54M | -$-6.46M | $32.5M | $7.29M | $2.24M |
| Net cash provided by operating activities | -$-897.74M | -$-557.44M | -$-350.57M | -$-224.4M | -$-147.18M |
| Investments in property, plant and equipment | -$-15.99M | -$-10.31M | -$-7.73M | -$-10.82M | -$-6.53M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $13.3M | $135.6M |
| Net cash used for investing activities | $118.1M | -$-554.39M | -$-342.6M | -$-24.12M | -$-142.12M |
| Common stock issued | $377.1M | $959.1M | $392.4M | $298.1M | $291.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $621.5M | $959.4M | $1.23B | $301.4M | $294.2M |
| Net change in cash | -$-158.16M | -$-153.08M | $534.7M | $52.9M | $4.88M |
| Cash at end of period | $388.6M | $543.1M | $696.2M | $163.2M | $110.2M |
| Operating cash flow | -$-897.74M | -$-557.44M | -$-350.57M | -$-224.4M | -$-147.18M |
| Capital expenditure | -$-15.99M | -$-10.31M | -$-7.73M | -$-10.82M | -$-6.53M |
| Free cash flow | -$-913.73M | -$-567.74M | -$-358.3M | -$-235.22M | -$-153.71M |
Line items
Line items
Line items
About Revolution Medicines, Inc. Warrant
Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation. The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds. Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D). Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets. In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.
- CEO
- Mark A. Goldsmith
- Employees
- 883
- Beta
- 1.40
Explore
Frequently asked questions
What is the intrinsic value of Revolution Medicines, Inc. Warrant (RVMDW)?
InvestorsCraft does not currently publish an intrinsic value for RVMDW. How the IC value is calculated.
Is RVMDW undervalued?
InvestorsCraft does not publish an undervaluation signal for RVMDW at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.